Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30039889 | 1.00 | ALDH1A1 (0.46) | ALDH1A1STSEPHX2HTTGPR119 | |
| SCHEMBL23112128 | 0.83 | CHRM2 (0.43) | ALDH1A1STSMEN1KMT2AMTNR1B | |
| SCHEMBL13138460 | 0.82 | NR1H2 (0.46) | ALDH1A1HTTGPR119MEN1KMT2A | |
| SCHEMBL17037848 | 0.82 | CHRM2 (0.40) | ALDH1A1GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL29865853 | 0.82 | CNR1 (0.46) | ALDH1A1STSHTTGPR119MEN1 | |
| SCHEMBL30040501 | 0.82 | CNR1 (0.46) | ALDH1A1STSHTTGPR119MEN1 | |
| SCHEMBL21465775 | 0.82 | HTT (0.43) | ALDH1A1STSEPHX2HTTGPR119 | |
| SCHEMBL353212 | 0.82 | ALDH1A1 (0.41) | ALDH1A1GPR119MEN1KMT2ACHRM2 | |
| SCHEMBL13137753 | 0.81 | GPR119 (0.47) | STSGPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL29865825 | 0.81 | ALDH1A1 (0.42) | ALDH1A1STSEPHX2HTTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109801-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | BLUE OAK PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-4084795-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | Blue Oak Pharmaceuticals, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109801-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | PMP22, CHAT, ACHE | ALDH1A1 1196/4885STS 2791/4885EPHX2 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.